InflaRx N.V. (IFRX)
Nasdaq: IFRX · Pharmaceutical Preparations · Jena, DE · filing with the SEC since 2017
Who runs InflaRx N.V.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Riedemann Niels
Chief Executive Officer. First filing Mar 2026, latest Mar 18, 2026, 0 filings in all.
Officers reporting now
4
of 9 people with a filing in the last fifteen months
Directors reporting now
5
9 people on the record since 2026
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Riedemann Niels | Chief Executive Officer | Mar 2026 | Mar 18, 2026 | none |
| Ocarroll Derval | Senior Vice President, Global Head of Regulatory Affairs and Compliance Exhibit List - Exhibit 24.1 Power of Attorney | Mar 2026 | Mar 18, 2026 | none |
| Taapken Thomas | Chief Financial Officer | Mar 2026 | Mar 18, 2026 | none |
| Guo Renfeng | Chief Scientific Officer | Mar 2026 | Mar 18, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Brudnick Richard | director | Mar 2026 | Mar 18, 2026 | none |
| Fulpius Nicolas | director | Mar 2026 | Mar 18, 2026 | none |
| Gibney Anthony S | director | Mar 2026 | Mar 18, 2026 | none |
| Hellstrom Hege | director | Mar 2026 | Mar 18, 2026 | none |
| Kubler Mark | director | Mar 2026 | Mar 18, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.